1. Beaulieu, J. et al. (2008) A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132:125--136
  2. Stone, E. (1763) An Account of the Success of the Bark of the Willow in the Cure of Agues. Phil. Trans. Roy. Soc. Lond. 53:195-200
  3. Fleming, A. (1929) On the antibacterial action of cultures of a Penicillium, with special reference to their use in isolation of B. influenzae. Br. J. Exp. Pathol. 10:226-236
  4. Brunel, J. (1951) Antibiosis from Pasteur to Fleming. J. Hist. Med. Allied Sci. 6:287-301
  5. Ehrlich, P. (1908) Partial cell functions. misc.
  6. Bickerton, R.K. (1963) The response of isolated strips of cat spleen to sympathomimetic drugs and their antagonists. J. Pharmacol. Exp. Ther. 142:99-9110
  7. Shapiro, D.A. et al. (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411
  8. Berg, K.A. et al. (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol. Pharmacol. 54:94-9104
  9. Strickland, S. and Loeb, J.N. (1981) Obligatory separation of hormone binding and biological response curves in systems dependent upon secondary mediators of hormone action. Proc. Natl. Acad. Sci. U. S. A. 78:1366-1370
  10. Brown, L. et al. (1992) Spare receptors for β-adrenoceptor-mediated positive inotropic effects of catecholamines in the human heart. J. Cardiovasc. Pharmacol. 19:222-232
  11. Katzung, B.G. (2001) Basic and Clinical Pharmacology (McGraw-Hill).
  12. Aller, S.G. et al. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718-1722
  13. Dawson, R.J.P. and Locher, K.P. (2007) Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett. 581:935-938
  14. Bihorel, S. et al. (2007) Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm. Res. 24:1720-1728
  15. Tröger, U. et al. (2005) Tetraparesis associated with colchicine is probably due to inhibition by verapamil of the P-glycoprotein efflux pump in the blood-brain barrier. BMJ 331:613
  16. Wada, D.R. et al. (1997) Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. Anesthesiology 87:884-899
  17. Frenia, M.L. et al. (1996) Multiple-dose activated charcoal compared to urinary alkalinization for the enhancement of phenobarbital elimination. J. Toxicol. Clin. Toxicol. 34:169-175
  18. Zuccato, E. et al. (2005) Cocaine in surface waters: a new evidence-based tool to monitor community drug abuse. Environ. Health 4:14
  19. Brunton, L.L. et al. (2005) Goodman and {Gilman}'s {The} pharmacological basis of therapeutics (McGraw Hill).
  20. He, K. et al. (1998) Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol. 11:252-259
  21. Ekroos, M. and Sjögren, T. (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. U. S. A. 103:13682-13687
  22. Chrencik, J.E. et al. (2005) Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol. Endocrinol. 19:1125-1134
  23. Bauer, J. et al. (2007) A structural gap in Dpo4 supports mutagenic bypass of a major benzo[a]pyrene dG adduct in DNA through template misalignment. Proc. Natl. Acad. Sci. U. S. A. 104:14905-14910
  24. McGill, M.R. and Jaeschke, H. (2013) Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharm. Res. 30:2174-87
  25. Goedde, H.W. et al. (1964) Studies on pharmacogenetics. I. The enzymatic acetylation of isonicotinic acid hydrazide (INH). Biochem. Pharmacol. 13:1671-1675
  26. Rashid, J.R. et al. (1992) Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital. East Afr. Med. J. 69:406-408
  27. Golka, K. et al. (2002) The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol. Lett. 128:229-241
  28. Mattano, S.S. et al. (1989) Purification and biochemical characterization of hepatic arylamine N-acetyltransferase from rapid and slow acetylator mice: identity with arylhydroxamic acid N,O-acyltransferase and N-hydroxyarylamine O-acetyltransferase. Mol. Pharmacol. 35:599-609
  29. Fu, Y. et al. (2005) Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954. Biochem. Biophys. Res. Commun. 336:332-338
  30. Hein, P. et al. (2006) Gs activation is time-limiting in initiating receptor-mediated signaling. J. Biol. Chem. 281:33345-33351
  31. Gether, U. et al. (1993) Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonist. Nature 362:345-348
  32. Hubbell, W.L. et al. (2003) Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv. Protein Chem. 63:243-290
  33. Arnis, S. et al. (1994) A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin. J. Biol. Chem. 269:23879-23881
  34. Chackalamannil, S. et al. (2005) Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J. Med. Chem. 48:5884-5887
  35. Galvez, T. et al. (2001) Allosteric interactions between GB1 and GB2 subunits are required for optimal GABAB receptor function. EMBO J. 20:2152-2159
  36. Ma, A.W.-.S. et al. (2007) Recovery of oligomers and cooperativity when monomers of the M2 muscarinic cholinergic receptor are reconstituted into phospholipid vesicles. Biochemistry 46:7907-7927
  37. Rajeswaran, W.G. et al. (2001) Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as selective muscarinic agonists. J. Med. Chem. 44:4563-4576
  38. Waldhoer, M. et al. (2005) A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. U. S. A. 102:9050-9055
  39. Dalpiaz, A. et al. (2012) A novel conjugated agent between dopamine and an A2A adenosine receptor antagonist as a potential anti-Parkinson multitarget approach. Mol. Pharm. 9:591-604
  40. Matkovich, S.J. et al. (2006) Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and β-adrenergic signaling. Circ. Res. 99:996-991003
  41. Shenoy, S.K. et al. (2006) β-Arrestin-dependent, G protein-independent ERK1/2 activation by the β2 adrenergic receptor. J. Biol. Chem. 281:1261-1273
  42. Piersol, G.A. (1908) Human Anatomy (Lippincott).
  43. dos Reis, A.J. (2009) Sigmund Freud (1856-1939) and Karl Kö{}ller (1857-1944) and the discovery of local anesthesia. Rev. Bras. Anestesiol. 59:244-257
  44. Zamponi, G.W. and French, R.J. (1993) Dissecting lidocaine action: diethylamide and phenol mimic separate modes of lidocaine block of sodium channels from heart and skeletal muscle. Biophys. J. 65:2335-2347
  45. Roy, M. et al. (1996) HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94:817-823
  46. Huang, L. et al. (2004) NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J. Pharmacol. Exp. Ther. 309:193-199
  47. SoRelle, R. (1998) Withdrawal of Posicor from market. Circulation 98:831-832
  48. Hannon, H.E. and Atchison, W.D. (2013) Omega-conotoxins as experimental tools and therapeutics in pain management. Mar. Drugs 11:680-699
  49. Willette, R.N. et al. (2008) Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: Part 2. J. Pharmacol. Exp. Ther. 326:443-452
  50. Skou, J.C. (1957) The influence of some cations on an adenosine triphosphatase from peripheral nerves. Biochim. Biophys. Acta 23:394-401
  51. Post, R.L. et al. (1972) Activation by adenosine triphosphate in the phosphorylation kinetics of sodium and potassium ion transport adenosine triphosphatase. J. Biol. Chem. 247:6530-6540
  52. Forbush, B. (1987) Rapid release of 42K and 86Rb from an occluded state of the Na,K-pump in the presence of ATP or ADP. J. Biol. Chem. 262:11104-11115
  53. Chiara, D.C. et al. (2003) Identification of amino acids in the nicotinic acetylcholine receptor agonist binding site and ion channel photolabeled by 4-[(3-trifluoromethyl)-3H-diazirin-3-yl]benzoylcholine, a novel photoaffinity antagonist. Biochemistry 42:271-283
  54. Katz, B. and Thesleff, S. (1957) A study of the desensitization produced by acetylcholine at the motor end-plate. J. Physiol. 138:63-80
  55. Foster, A.C. and Kemp, J.A. (2006) Glutamate- and GABA-based CNS therapeutics. Curr. Opin. Pharmacol. 6:7-17
  56. Stähle, H. (2000) A historical perspective: development of clonidine. Best Pract. Res. Clin. Anaesthesiol. 14:237 - 246
  57. Sulzer, D. et al. (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75:406-433
  58. Robinson, R.L. (1966) Stimulation of the release of catecholamines from isolated adrenal glands by tyramine. J. Pharmacol. Exp. Ther. 151:55-58
  59. Nilsson, B. et al. (2011) G protein-coupled oestrogen receptor 1 (GPER1/GPR30): a new player in cardiovascular and metabolic oestrogenic signalling. Br. J. Pharmacol. 163:1131-1139
  60. Reddy, D.S. (2010) Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog. Brain Res. 186:113-137
  61. Vayssière, B.M. et al. (1997) Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol. Endocrinol. 11:1245-1255
  62. Janka-Junttila, M. et al. (2006) The glucocorticoid RU24858 does not distinguish between transrepression and transactivation in primary human eosinophils. J. Inflamm. Lond. 3:10
  63. King, E.M. et al. (2013) Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms. PLoS One 8:e53936
  64. Clapauch, R. et al. (2009) Total estradiol, rather than testosterone levels, predicts osteoporosis in aging men. Arq. Bras. Endocrinol. Metabol. 53:1020-1025
  65. Sanz-Rodríguez, C.E. et al. (2007) Bisphosphonates as inhibitors of Trypanosoma cruzi hexokinase: kinetic and metabolic studies. J. Biol. Chem. 282:12377-12387
  66. Pérez-Castrillón, J.L. et al. (2007) Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am. J. Cardiol. 99:903-905
  67. Lin, T. et al. (2018) Long-term effect of statins on the risk of new-onset osteoporosis: A nationwide population-based cohort study. PLoS One 13:e0196713
  68. Jaffrey, S.R. et al. (2001) Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat. Cell Biol. 3:193-197
  69. Chen, Z. et al. (2002) Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc. Natl. Acad. Sci. U. S. A. 99:8306-8311
  70. Minamiyama, Y. et al. (2007) Cytochrome P450 is responsible for nitric oxide generation from NO-aspirin and other organic nitrates. Drug Metab. Pharmacokinet. 22:15-19
  71. Schrammel, A. et al. (1998) Activation of soluble guanylyl cyclase by the nitrovasodilator 3-morpholinosydnonimine involves formation of S-nitrosoglutathione. Mol. Pharmacol. 54:207-212
  72. Cuzzocrea, S. et al. (2002) Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis. Eur. J. Pharmacol. 453:119-129
  73. Langenbach, R. et al. (1995) Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83:483-492
  74. Morham, S.G. et al. (1995) Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83:473-482
  75. Rowlinson, S.W. et al. (2003) A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J. Biol. Chem. 278:45763-45769
  76. Serhan, C.N. (2005) Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot. Essent. Fatty Acids 73:141-162
  77. Loo, Y.H. (1974) Serotonin deficiency in experimental hyperphenylalaninemia. J. Neurochem. 23:139-147
  78. Woolf, L.I. (1986) The heterozygote advantage in phenylketonuria. Am. J. Hum. Genet. 38:773-775
  79. Kohn, D.B. and Gaspar, H.B. (2017) How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID). J. Clin. Immunol. -:n/a
  80. Joachims, M.L. et al. (2008) Inhibition of deoxynucleoside kinases in human thymocytes prevents dATP accumulation and induction of apoptosis. Nucleosides Nucleotides Nucleic Acids 27:816-820
  81. Löffler, W. et al. (1982) Influence of dietary purines on pool size, turnover, and excretion of uric acid during balance conditions. Isotope studies using 15N-uric acid. Res. Exp. Med. Berl 181:113-123
  82. Mehlhaff, D.L. and Stein, D.S. (1996) Gout secondary to ritonavir and didanosine. AIDS 10:1744
  83. Choi, H.K. et al. (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363:1277-1281
  84. Kishibe, M. et al. (2010) Chronic tophaceous gout secondary to self-induced vomiting in anorexia nervosa. J. Dermatol. 37:578-580
  85. Heuckenkamp, P.U. and Zöllner, N. (1971) Fructose-induced hyperuricaemia. Lancet 1:808-809
  86. Oberhaensli, R.D. et al. (1987) Study of hereditary fructose intolerance by use of 31P magnetic resonance spectroscopy. Lancet 2:931-934
  87. Choi, H.K. and Curhan, G. (2008) Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 336:309-312
  88. Barranger, J.A. and O'Rourke, E. (2001) Lessons learned from the development of enzyme therapy for Gaucher disease. J. Inherit. Metab. Dis. 24 Suppl 2:89-96
  89. Colca, J.R. et al. (2013) Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT) –relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One 8:e61551
  90. Divakaruni, A.S. et al. (2013) Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc. Natl. Acad. Sci. U. S. A. 110:5422-5427
  91. Miller, R.A. et al. (2013) Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494:256-260
  92. Palmer, M. (2003) Efflux of cytoplasmically acting antibiotics from gram-negative bacteria: periplasmic substrate capture by multicomponent efflux pumps inferred from their cooperative action with single-component transporters. J. Bacteriol. 185:5287-5289
  93. Marquardt, J.L. et al. (1994) Kinetics, stoichiometry, and identification of the reactive thiolate in the inactivation of UDP-GlcNAc enolpyruvoyl transferase by the antibiotic fosfomycin. Biochemistry 33:10646-10651
  94. Goff, D.C. (2012) D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophr. Bull. 38:936-941
  95. Johnson, J.W. et al. (2010) Cyclobutanone analogues of β-lactams revisited: insights into conformational requirements for inhibition of serine- and metallo-β-lactamases. J. Am. Chem. Soc. 132:2558-2560
  96. Sulton, D. et al. (2005) Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 β-lactamase. Insights into the mechanism of inhibition. J. Biol. Chem. 280:35528-35536
  97. Xie, J. et al. (2011) A redesigned vancomycin engineered for dual D-Ala-D-ala And D-Ala-D-Lac binding exhibits potent antimicrobial activity against vancomycin-resistant bacteria. J. Am. Chem. Soc. 133:13946-13949
  98. Zhanel, G.G. et al. (2010) New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70:859-86
  99. Palmer, A.C. and Kishony, R. (2014) Opposing effects of target overexpression reveal drug mechanisms. Nat. Commun. 5:4296
  100. Muraih, J.K. et al. (2011) Oligomerization of daptomycin on membranes. Biochim. Biophys. Acta 1808:1154-1160
  101. Zhang, T. et al. (2013) Mutual inhibition through hybrid oligomer formation of daptomycin and the semisynthetic lipopeptide antibiotic CB-182,462. Biochim. Biophys. Acta 1828:302-308
  102. Grein, F. et al. (2020) Ca2+-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids. Nat. Commun. 11:1455
  103. Zhang, T. et al. (2014) Daptomycin forms cation- and size-selective pores in model membranes. Biochim. Biophys. Acta 1838:2425-2430
  104. Teerlink, T. et al. (1980) The action of pimaricin, etruscomycin and amphotericin B on liposomes with varying sterol content. Biochim. Biophys. Acta 599:484-492
  105. Walev, I. and Bhakdi, S. (1996) Possible reason for preferential damage to renal tubular epithelial cells evoked by amphotericin B. Antimicrob. Agents Chemother. 40:1116-1120
  106. Uhlemann, A. et al. (2005) A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat. Struct. Mol. Biol. 12:628-629
  107. Cui, L. et al. (2012) Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins. Antimicrob. Agents Chemother. 56:2546-52
  108. Luque-Ortega, J.R. and Rivas, L. (2007) Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 51:1327-1332
  109. Hoang, A.N. et al. (2010) The neutral lipid composition present in the digestive vacuole of Plasmodium falciparum concentrates heme and mediates \gb-hematin formation with an unusually low activation energy. Biochemistry 49:10107-10116
  110. Kapishnikov, S. et al. (2012) Oriented nucleation of hemozoin at the digestive vacuole membrane in Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 109:11188-11193
  111. Gildenhuys, J. et al. (2013) The Single Crystal X-ray Structure of \gb-Hematin DMSO Solvate Grown in the Presence of Chloroquine, a \gb-Hematin Growth-Rate Inhibitor. J. Am. Chem. Soc. 135:1037-1047
  112. Müller, M. (1993) The hydrogenosome. J. Gen. Microbiol. 139:2879-2889
  113. Edwards, D.I. (1980) Mechanisms of selective toxicity of metronidazole and other nitroimidazole drugs. Br. J. Vener. Dis. 56:285-290
  114. Fairlamb, A.H. et al. (1989) Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc. Natl. Acad. Sci. U. S. A. 86:2607-2611
  115. Mukhopadhyay, R. et al. (1996) Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc. Natl. Acad. Sci. U. S. A. 93:10383-10387
  116. Dwyer, J.J. et al. (2007) Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. U. S. A. 104:12772-12777
  117. Issaeva, N. et al. (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10:1321-1328
  118. Janssen, K. et al. (2007) Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment. Blood 110:3662-3672
  119. Svingen, P.A. et al. (2000) Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin. Cancer Res. 6:237-249
  120. Ostrowski, M.L. et al. (1999) Malignant chondroblastoma presenting as a recurrent pelvic tumor with DNA aneuploidy and p53 mutation as supportive evidence of malignancy. Skeletal Radiol. 28:644-650
  121. Giudici, D. et al. (1988) 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J. Steroid Biochem. 30:391-394
  122. Nasr, R. et al. (2008) Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat. Med. 14:1333-1342
  123. Galmarini, C.M. et al. (2002) In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br. J. Haematol. 117:860-868
  124. Cline, S.D. and Osheroff, N. (1999) Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes. J. Biol. Chem. 274:29740-29743
  125. Frankland-Searby, S. and Bhaumik, S.R. (2012) The 26S proteasome complex: an attractive target for cancer therapy. Biochim. Biophys. Acta 1825:64-76
  126. Terrano, D.T. et al. (2010) Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol. Cell. Biol. 30:640-656
  127. Fourmy, D. et al. (1996) Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 274:1367-1371
  128. Krebs, A. et al. (2003) Targeting the HIV trans-activation responsive region–approaches towards RNA-binding drugs. Chembiochem 4:972-978
  129. Welch, E.M. et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87-91
  130. Goldmann, T. et al. (2012) A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation. EMBO Mol. Med. 4:1186-1199
  131. Kerem, E. et al. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372:719-727
  132. Thakral, S. et al. (2013) Eudragit: a technology evaluation. Expert Opin. Drug Deliv. 10:131-149
  133. Ibrahim, A.S. et al. (2003) Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob. Agents Chemother. 47:3343-3344
  134. Denning, D.W. and Warn, P. (1999) Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. Antimicrob. Agents Chemother. 43:2592-2599
  135. Barenholz, Y. (2012) Doxil®{}—{}the first FDA-approved nano-drug: lessons learned. J. Control. Release 160:117-134
  136. Dedon, P.C. et al. (1993) Exclusive production of bistranded DNA damage by calicheamicin. Biochemistry 32:3617-3622
  137. Liu, K. et al. (2010) High-throughput screening for Kv1.3 channel blockers using an improved FLIPR-based membrane-potential assay. J. Biomol. Screen. 15:185-195
  138. Tanino, T. et al. (2011) Mechanistic analysis of muraymycin analogues: a guide to the design of MraY inhibitors. J. Med. Chem. 54:8421-8439
  139. McDaniel, R. et al. (1999) Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel "unnatural" natural products. Proc. Natl. Acad. Sci. U. S. A. 96:1846-1851
  140. Wang, D. (2008) Neurotoxins from marine dinoflagellates: a brief review. Mar. Drugs 6:349-371
  141. Kaplan, A.P. and Bartlett, P.A. (1991) Synthesis and evaluation of an inhibitor of carboxypeptidase A with a Ki value in the femtomolar range. Biochemistry 30:8165-8170
  142. Trott, O. and Olson, A.J. (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31:455-461
  143. Sufrin, J.R. et al. (1981) Steric mapping of the L-methionine binding site of ATP:L-methionine S-adenosyltransferase. Mol. Pharmacol. 19:307-313
  144. Mazzone, J. (2006) Copyfraud. N. Y. Univ. Law Rev. 81:1026-1098
  145. Rubin, R.P. (2007) A brief history of great discoveries in pharmacology: in celebration of the centennial anniversary of the founding of the American Society of Pharmacology and Experimental Therapeutics. Pharmacol. Rev. 59:289-359